Ki-67 IHC pharmDx
Agilent Technologies, Inc. · Decision date Oct 12, 2021
What did the FDA approve?
FDA records P210026 as an original PMA application. The recorded decision is approval, dated Oct 12, 2021.
FDA approval order statement
Approval of Ki-67 IHC MIB-1 pharmDx (Dako Omnis)For In Vitro Diagnostic Use.Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is a qualitative immunohistochemical (IHC) assay using monoclonal mouse anti-Ki-67, Clone MIB-1, intended for use in the detection of Ki-67 protein in formalin-fixed, paraffin-embedded (FFPE) breast carcinoma tissue using the EnVision FLEX visualization system on Dako Omnis.Ki-67 protein expression in breast carcinoma is determined by using the Ki-67 pharmDx Score, which is the overall percentage of viable tumor cells in the invasive cancer component showing Ki-67 nuclear staining. The specimen should be considered to have Ki-67 expression if Ki-67 pharmDx Score is ? 20.Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is indicated as an aid in identifying patients with early breast cancer at high risk of disease recurrence for whom adjuvant treatment with Verzenio (abemaciclib) in combination with endocrine therapy is being considered.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Pathology
- Decision date
- Oct 12, 2021
Regulatory record facts
- Identifier
- P210026
- Regulatory pathway
- Premarket approval application
- Applicant
- Agilent Technologies, Inc.
- Product code
- QQT
- Decision code
- APPR
- Decision date
- Oct 12, 2021
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Immunohistochemistry assay, antibody, Ki-67.
- Applicant
- Agilent Technologies, Inc.
- Product code
- QQT
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P210026 received
Application receipt date recorded by FDA.
P210026 · FDA decision
APPR
P210026/S003 · Related supplement
Ki-67 IHC MIB-1 pharmDx (Dako Omnis)
Timeline entries are records held by MedtechLedger for P210026. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210026
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Ki-67 IHC MIB-1 pharmDx (Dako Omnis)P210026/S003 | Agilent Technologies, Inc. | PMA supplement | Sep 11, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Agilent Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5301 Stevens Creek Blvd., Santa Clara, CA, 95051
Sources and methodology
- Original FDA record: P210026
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records